title: Decreased urinary glycosaminoglycan excretion following alfuzosin treatment on ureteral stent-related symptoms: a prospective, randomized, placebo-controlled study.
abstract: The objectives of the study were to evaluate changes in ureteral stent-related symptoms and urinary glycosaminoglycan (GAG) excretion after alfuzosin treatment, and to further investigate the relationship between stent-related symptoms and loss of urinary GAGs. Seventy consecutive patients scheduled for unilateral retrograde ureteroscopy with stent placement were recruited. Patients were randomly assigned to treatment with alfuzosin 10 mg/day or placebo for 3 weeks starting on the third postoperative day. The ureteral stent was removed when treatment stopped. International Prostate Symptom Score (IPSS), visual analog scale (VAS) score, and urinary GAG excretion were determined before treatment at 1, 2, and 3 weeks after treatment, and at 3 weeks after stent removal. Fifty-nine patients completed the study. IPSS, VAS score, and urinary GAG excretion were significantly lower in the alfuzosin group, compared with the placebo group, at 1, 2, and 3 weeks after treatment (P < 0.01). In both groups, IPSS, VAS score, and urinary GAG excretion were significantly lower at 3 weeks after stent removal compared with those before stent removal. No significant differences in IPSS, VAS score, or urinary GAG excretion were observed between the two groups at baseline and 3 weeks after stent removal (P > 0.05). Positive correlations were found between urinary GAG excretion (R(2) = 0.65, P < 0.001) and IPSS and between urinary GAG excretion and VAS score (R(2) = 0.33, P < 0.001). Stent placement contributes to loss of urinary GAGs. However, alfuzosin effectively reduces such loss and improves ureteral stent-related symptoms. Loss of urinary GAGs plays a role in these symptoms.
authors.affiliation: Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jie-Fang Avenue, Wuhan, 430022, China.
authors.forename: Shucheng
authors.initials: S
authors.lastname: Liu
authors.affiliation: Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jie-Fang Avenue, Wuhan, 430022, China.
authors.forename: Ying
authors.initials: Y
authors.lastname: Yu
authors.affiliation: Division of Histology and Embryology, Department of Anatomy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
authors.forename: Yang
authors.initials: Y
authors.lastname: Gao
authors.affiliation: Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jie-Fang Avenue, Wuhan, 430022, China.
authors.forename: Xiong
authors.initials: X
authors.lastname: Yang
authors.affiliation: Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jie-Fang Avenue, Wuhan, 430022, China. zilipang21@163.com.
authors.forename: Zili
authors.initials: Z
authors.lastname: Pang
mesh_terms: D000328:Adult; D004311:Double-Blind Method; D005260:Female; D006025:Glycosaminoglycans / Q000652:urine*; D006417:Hematuria / Q000188:drug therapy / Q000209:etiology; D006801:Humans; D059411:Lower Urinary Tract Symptoms / Q000188:drug therapy* / Q000209:etiology / Q000652:urine; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011799:Quinazolines / Q000008:administration & dosage / Q000627:therapeutic use*; D012735:Sexual Dysfunction, Physiological / Q000188:drug therapy / Q000209:etiology; D015607:Stents / Q000009:adverse effects*; D011795:Surveys and Questionnaires; D013577:Syndrome; D016896:Treatment Outcome; D014513:Ureter / Q000601:surgery; D014514:Ureteral Calculi / Q000601:surgery; D014515:Ureteral Diseases / Q000188:drug therapy* / Q000209:etiology / Q000652:urine; D018666:Ureteroscopy / Q000009:adverse effects* / Q000295:instrumentation / Q000379:methods; D001743:Urinary Bladder / Q000293:injuries*; D064804:Urological Agents / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D006025:Glycosaminoglycans; D011799:Quinazolines; D064804:Urological Agents; C047638:alfuzosin
keywords: Alfuzosin; Glycosaminoglycan excretion; Lower urinary tract symptoms; Ureteral stent